



(11) **EP 1 363 925 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

- (15) Correction information:
Corrected version no 1 (W1 B1)
INID code(s) 73
- (48) Corrigendum issued on:
25.04.2007 Bulletin 2007/17
- (45) Date of publication and mention
of the grant of the patent:
15.11.2006 Bulletin 2006/46
- (21) Application number: **01271380.6**
- (22) Date of filing: **20.12.2001**
- (51) Int Cl.:
C07H 17/08 (2006.01) A61K 31/70 (2006.01)
- (86) International application number:
PCT/GB2001/005665
- (87) International publication number:
WO 2002/050091 (27.06.2002 Gazette 2002/26)

(54) **MACROLIDE ANTIBIOTICS**

MAKROLIDANTIBIOTIKA

ANTIBIOTIQUES A BASE DE MACROLIDES

- | | |
|---|--|
| <p>(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR
Designated Extension States:
SI</p> <p>(30) Priority: 21.12.2000 GB 0031309
01.11.2001 GB 0126277
01.11.2001 GB 0126276</p> <p>(43) Date of publication of application:
26.11.2003 Bulletin 2003/48</p> <p>(73) Proprietors:
• GLAXO GROUP LIMITED
Greenford, Middlesex UB6 ONN (GB)
• GlaxoSmithKline istrazivacki centar Zagreb
d.o.o.
10000 Zagreb (HR)</p> <p>(72) Inventors:
• ANDREOTTI, Daniele,
GlaxoSmithKline SpA
I-37100 Verona (IT)
• ARISTA, Luca,
GlaxoSmithKline SpA
I-37100 Verona (IT)
• BIONDI, Stefano,
GlaxoSmithKline SpA
I-37100 Verona (IT)</p> | <ul style="list-style-type: none">• CARDULLO, Francesca,
GlaxoSmithKline SpA
I-37100 Verona (IT)• DAMIANI, Frederica,
GlaxoSmithKline SpA
I-37100 Verona (IT)• LOCIURO, Sergio,
GlaxoSmithKline SpA
I-37100 Verona (IT)• MARCHIORO, Carla,
GlaxoSmithKline SpA
I-37100 Verona (IT)• MERLO, Giancarlo,
GlaxoSmithKline SpA
I-37100 Verona (IT)• MINGARDI, Anna,
GlaxoSmithKline SpA
I-37100 Verona (IT)• NICCOLAI, Daniela,
GlaxoSmithKline SpA
I-37100 Verona (IT)• PAIO, Alfredo,
GlaxoSmithKline SpA
I-37100 Verona (IT)• PIGA, Elisabetta,
GlaxoSmithKline SpA
I-37100 Verona (IT)• POZZAN, Alfonso,
GlaxoSmithKline SpA
I-37100 Verona (IT) |
|---|--|

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 363 925 B8

- **SERI, Catia,**
GlaxoSmithKline SpA
I-37100 Verona (IT)
- **TARSI, Luca,**
GlaxoSmithKline SpA
I-37100 Verona (IT)
- **TERRENI, Silvia,**
GlaxoSmithKline SpA
I-37100 Verona (IT)
- **TIBASCO, Jessica,**
GlaxoSmithKline SpA
I-37100 Verona (IT)
- **CIRACO, Manuela,**
c/o BPB Italia S.p.A.
20090 Settala (IT)

(74) Representative: **Gladwin, Amanda Rachel et al**
GlaxoSmithKline
Corporate Intellectual Property
CN925.1
980 Great West Road
Brentford, Middlesex TW8 9GS (GB)

(56) References cited:

EP-A- 1 114 826	WO-A-00/44761
WO-A-99/21869	WO-A-99/21870
FR-A- 2 732 684	US-A- 5 747 467